



Blood Products and Cellular Therapies: A Symposium on Emergency Preparedness

Co-hosted by BARDA and NHLBI - November 15-16, 2012
Natcher Conference Center, NIH Building 45 - Bethesda, MD

AGENDA

DAY 1 – Session A: Blood Products: Emergency Plans and Use

Discussion Leader: Joanna Prasher, PhD (Branch Chief, Medical Countermeasures Strategy and Requirements Division, Office of the Assistant Secretary for Preparedness and Response, HHS)

7:30 AM: **ARRIVAL / CHECK-IN**

8:00 AM: ***Welcome and Introductions***

- Robin Robinson, PhD (Director, BARDA)
- W. Keith Hoots, MD (Director, Division of Blood Diseases and Resources, NHLBI/NIH)

8:30 AM: ***Plenary Lecture: “Disaster Preparedness: Blood Components and Cellular Therapy”***

- Harvey Klein, MD (Chief, Department of Transfusion Medicine, Clinical Center, National Institutes of Health)

9:10 AM: ***“FDA Regulation of Blood and Blood Components in the United States”***

- Ginette Michaud, MD (Deputy Director, Office of Blood Research and Review, CBER/FDA)

9:30 AM: ***“Use of Blood Products and Cellular Therapies in an Emergency”***

- Cynthia Kelley, MS (Senior Advisor for Counterterrorism/Medical Countermeasures, CBER/FDA)

9:50 AM: **BREAK**

10:00 AM: ***“Emergency Preparedness: Role of the AABB Interorganizational Task Force on Domestic Disasters and Acts of Terrorism”***

- Karen Shoos, JD (Chief Executive Officer, AABB)

10:20 AM: ***“American Red Cross Biomedical Services Emergency Operations Planning”***

- Richard Benjamin, MD, PhD (Chief Medical Officer, American Red Cross)

10:40 AM: ***“Testing Blood Donor Samples in an Emergency”***

- Peter Tomasulo, MD (Chief Medical and Scientific Officer, Blood Systems)

11:00 AM: ***“Emergency Case Studies: New York Blood Center”***

- Beth Shaz, MD (Chief Medical Officer, New York Blood Center)

11:20 AM: ***“Military Blood Support in War & Peace: Lessons Learned”***

- Col Richard McBride (Director, Armed Services Blood Program Office)

11:40 AM: ***“Medical Response to a Nuclear Detonation: Organization and Tools Developed Through ASPR and Collaborators”***

- Norm Coleman, MD (Senior Medical Advisor, OPEO/ASPR/HHS)

12:00 PM: ***“Radiation Injury Treatment Network: Leveraging Existing Expertise to Provide Radiation Casualty Management”***

- David Weinstock, MD (Medical Advisor, Radiation Injury Treatment Network; Assistant Professor, Dana Farber Cancer Institute)

12:30 PM: LUNCH – Panel Deliberation (Conference Room A)

1:20 PM: PANEL DISCUSSION – SESSION A

DAY 1 – Session B: Cellular Therapies with a Focus on Marrow Replacement

Discussion Leader: Harvey Klein, MD (Chief, Department of Transfusion Medicine, Clinical Center/NIH)

2:00 PM: “Allogeneic Stem Cell Transplantation in the Event of a Nuclear Disaster”

- Minoo Battiwalla, MD (Principal Investigator and Staff Clinician, Hematology Branch, NHLBI, NIH)

2:30 PM: “Manufacture of HPCs for Transplantation as Part of Emergency Preparedness: Issues to Consider”

- Edward Snyder, MD (Director, Transfusion/Apheresis/Tissue/Cell Processing Services, Yale-New Haven Hospital; Professor, Yale University Medical School)

3:00 PM: BREAK

3:20 PM “Development of ‘Cordbridge,’ a Product for Temporary or Permanent Rescue of Hematopoiesis after Severe Bone Marrow Injury”

- Joanne Kurtzberg, MD (Director, DTRI Cell and Tissue Therapies Core; Chief, Division of Pediatric Blood and Marrow Transplantation, Duke University Medical Center)

3:40 PM: “Notch-mediated Ex Vivo Expansion of Cord Blood Progenitor Cells Capable of Rapid Myeloid Reconstitution In Vivo”

- Colleen Delaney, MD (Director, Cord Blood Transplant Program, Fred Hutchinson Cancer Research Center)

4:00 PM: “Development and Licensure of Cellular Therapies”

- Keith Wonnacott, PhD (Division of Cellular and Gene Therapies, CBER/FDA)

4:20 PM: PANEL DISCUSSION – SESSION B

5:00 PM: CLOSING COMMENTS / ADJOURNMENT

DAY 2 – Session C: Red Blood Cells and Plasma

Discussion Leader: Simone Glynn, MD, MSc, MPH (Branch Chief, Transfusion Medicine and Cellular Therapeutics Branch, NHLBI/NIH)

8:00 AM: ARRIVAL / CHECK-IN

8:30 AM “New Insights into Mechanisms of the Red Blood Cell Storage Lesion”

- Mark Gladwin, MD (Chief, Pulmonary, Allergy and Critical Care Medicine Division, University of Pittsburgh School of Medicine)

9:10 AM: “Red Cells and Red Cell Substitutes”

- John Hess, MD, MPH (Associate Director, University of Maryland Medical Center Blood Bank; Professor, Pathology, University of Maryland Medical Center)

9:30 AM: “Blood Pharming: Novel Technologies for Production and Modification of Red Blood Cells”

- Renee Wegrzyn, PhD (Science Advisor, Defense Advanced Research Projects Agency/DSO)
- Stewart Abbot, PhD, MSc (Executive Director, Stem Cell Research, Celgene)

9:50 AM “Optimal use of Plasma after Severe Injury: Current, Mass Casualty, and the Future”

- John Holcomb, MD (Chair in Surgery, Professor and Vice Chair of the Department of Surgery, Chief of the Division of Acute Care Surgery, Director, Center for Translational Injury Research, University of Texas Medical School- Houston)

10:10 AM: BREAK

- 10:20 AM ***“Plasma Processing—Challenges for Emergency Preparedness”***
 - Toby Simon, MD (Senior Medical Director, Plasma and Plasma Safety, CSL Behring)
- 11:00 AM: ***“Novel Plasma Products To Support Treatment Of Military and Civilian Trauma”***
 - Larry Corash, MD (Senior Vice-President, Chief Medical Officer, Chief Scientific Officer, Cerus Corporation)
- 11:20 AM: **PANEL DISCUSSION – SESSION C**
- 12:00 PM: **LUNCH**

DAY 2 – Session D: Platelets

Discussion Leader: W. Keith Hoots, MD (Director, Division of Blood Diseases and Resources, NHLBI/NIH)

- 1:00 PM: ***“Cryopreserved, 4°C, and 22°C Extended Stored Platelets”***
 - Sherrill Slichter, MD (Director, Platelet Transfusion Research, Puget Sound Blood Center; Professor of Medicine, University of Washington School of Medicine)
- 1:40 PM ***“Overview of Thrombopoietic Products”***
 - Jim Bussel, MD (Professor and Attending Pediatrician, Weill Cornell Medical College)
- 2:10 PM: ***“Use of Ex vivo expanded Megakaryocyte Progenitors for the Treatment of Thrombocytopenia”***
 - Holger Karsunky, PhD (Director, Preclinical Development, Cellerant Therapeutics)
- 2:30 PM: ***“Stabilization of Platelets for Processing into a Freeze-Dried Infusible Hemostatic Agent”***
 - Art Bode, PhD (Chief Scientific Officer, Entegron, Inc.)
- 2:50 PM: ***“Current Status and Future Potential of a Freeze-Dried, Platelet-Derived, Hemostatic Agent”***
 - Michael Fitzpatrick, PhD (COL, Ret., US Army; President and Director of Clinical Research and Development, Cellphire Inc.)
- 3:10 PM: **BREAK**
- 3:20 PM: **PANEL DISCUSSION – SESSION D**

DAY 2 – Session E: Pathogen Reduction

Discussion Leader: Traci Mondoro, PhD (Deputy Branch Chief, Transfusion Medicine and Cellular Therapeutics Branch, NHLBI/NIH)

- 4:00 PM: ***“Considering the Prospects for Pathogen Reduction of Blood in Emergency Situations”***
 - Stephen Wagner, PhD (Head, Blood Components Department, Holland Laboratories, American Red Cross)
- 4:20 PM: ***“Pathogen Inactivation of Platelet Components: Role In Emergency Preparedness”***
 - Larry Corash, MD (Senior Vice-President, Chief Medical Officer, Chief Scientific Officer, Cerus Corporation)
- 4:40 PM: ***“Assuring a Safe, Effective and Adequate Supply of Blood Products in Disaster”***
 - Ray Goodrich, PhD (Vice President, Scientific and Clinical Affairs, Terumo BCT, Inc.)
- 5:00 PM: **PANEL DISCUSSION**
- 5:30 PM: **CLOSING COMMENTS / ADJOURNMENT**
